Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 719 matching trials from the live ClinicalTrials.gov search.
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Conditions
Neuromyelitis Optica
Interventions
NMOSDCopilot smartphone application
Device
Lead sponsor
Ad scientiam
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Tampa, Florida + 7 more
Conditions
Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
Interventions
Melphalan, Percutaneous Hepatic Perfusion
Drug · Device
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
U.S. locations
6
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 3 more
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Innovations in Glaucoma Study

NCT00221897
Conditions
Primary Open Angle Glaucoma, Myopia
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2030
U.S. locations
1
States / cities
La Jolla, California
Conditions
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Interventions
IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect®
Biological · Drug · Device
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Miami, Florida + 8 more
Conditions
Choroidal Melanoma, Indeterminate Lesions of Eye
Interventions
Not listed
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
Interventions
Pembrolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Terminated Phase 1 Interventional Results available

Ipilimumab and Local Radiation for Selected Solid Tumors

NCT01769222
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Melanoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
Ipilimumab, Radiation therapy
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Convergence Insufficiency, Binocular Vision Disorder
Interventions
Home-based Pencil Push-Up Therapy, Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics, Office-based Vision Therapy/Orthoptics, Placebo Office-based Vision Therapy/Orthoptics
Behavioral
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
9 Years to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 6 more
Conditions
Glaucoma, Intraocular Pressure, Optic Neuropathy
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
cixutumumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Months to 30 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
93
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Conditions
PSP, CBD, Progressive Supranuclear Palsy, FTD, Corticobasal Degeneration, Frontotemporal Dementia, Frontotemporal Lobar Degeneration
Interventions
PAMSys, LEGSys
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Vorinostat
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee
Conditions
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions
ER-100 epigenetic therapy
Genetic
Lead sponsor
Life Biosciences Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Glendale, California • Boston, Massachusetts • New York, New York + 1 more
Completed No phase listed Observational Accepts healthy volunteers

Tracking Neurodegeneration in Early Wolfram Syndrome

NCT02455414
Conditions
Type 1 Diabetes, Diabetes Insipidus, Diabetes Mellitus, Wolfram Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Palsy Supranuclear, Supranuclear Palsy, Progressive
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions
interferon beta 1a 30 ug IM once weekly
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
20
States / cities
Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more
Conditions
Neuromyelitis Optica, Devic's Disease
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Progressive Supranuclear Palsy
Interventions
Salsalate
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon